Results 271 to 280 of about 73,607 (303)

JAK2 in Myeloproliferative Neoplasms: Still a Protagonist [PDF]

Pharmaceuticals, 2022
The discovery of the activating V617F mutation in Janus kinase 2 (JAK2) has been decisive for the understanding of myeloproliferative neoplasms (MPN).
Sara C Meyer
exaly   +2 more sources

JAK2 V617F impairs hematopoietic stem cell function in a conditional knock-in mouse model of JAK2 V617F–positive essential thrombocythemia

Blood, 2010
The JAK2 V617F mutation is found in most patients with a myeloproliferative neoplasm and is sufficient to produce a myeloproliferative phenotype in murine retroviral transplantation or transgenic models.
Philip A Beer, Cedric Ghevaert, E Chen
exaly   +2 more sources

Mechanisms of Resistance to JAK2 Inhibitors in Myeloproliferative Neoplasms

Hematology/Oncology Clinics of North America, 2017
Myeloproliferative neoplasms are driven by activated JAK2 signaling due to somatic mutations in JAK2, the thrombopoietin receptor MPL or the chaperone calreticulin in hematopoietic stem/progenitor cells.
Sara C Meyer
exaly   +2 more sources

Some of the next articles are maybe not open access.

Related searches:

The JAK2 mutation

2021
Myeloproliferative neoplasms (MPNs) are clonal hematopoietic stem cell (HSC) disorders with overproduction of mature myeloid blood cells, including essential thrombocythemia (ET), polycythemia vera (PV), and primary myelofibrosis (PMF). In 2005, several groups identified a single gain-of-function point mutation JAK2V617F in the majority of MPN patients.
openaire   +2 more sources

JAK2 L884P Mutation Confers Resistance To The Type II JAK2 Inhibitor NVP-BBT594 When Co-Occurring With JAK2 R683G But Not JAK2 V617F

Blood, 2013
Abstract Approximately 50% of myeloproliferative neoplasms (MPNs) harbor the JAK2 V617F mutation while approximately 50% of B-cell acute lymphoblastic leukemias (B-ALLs) with CRLF2 rearrangements harbor JAK2 exon 16 mutations that primarily involve R683.
Nadja Kopp, Jordy C. Van der Zwet, Jacob Layer, Oliver Weigert, Eric Vangrevelinghe, Akinori Yoda, Thomas Radimerski, David Weinstock   +7 more
openaire   +1 more source

JAK2 Inhibitors: A Reality? A Hope?

Clinical Lymphoma and Myeloma, 2009
Myelofibrosis (MF; primary or post-polycythemia vera/essential thrombocythemia) carries the worst prognosis among BCR-ABL-negative myeloproliferative neoplasms (MPNs). Stem cell transplantation is the only curative approach but is hampered by significant nonrelapse mortality. Thus, effective, targeted therapies are needed.
Effrosyni, Apostolidou, Hagop M, Kantarjian, Srdan, Verstovsek   +2 more
openaire   +2 more sources

Roles of germline JAK2 activation mutation JAK2 V625F in the pathology of myeloproliferative neoplasms

International Journal of Biological Macromolecules, 2018
Janus tyrosine kinase 2 (JAK2) mediates downstream signaling of cytokine receptors in all hematological lineages, constitutively active somatic JAK2 mutations play key roles in the pathology of myeloproliferative neoplasms (MPNs). Recently, germline JAK2 mutations are also associated with triple-negative MPNs.
Qing-Yun, Wu, Meng-Meng, Ma, Lin, Fu, Yuan-Yuan, Zhu, Yang, Liu, Jiang, Cao, Ping, Zhou, Zhen-Yu, Li, Ling-Yu, Zeng, Feng, Li, Xiao-Yun, Wang, Kai-Lin, Xu   +11 more
openaire   +2 more sources

Clonal heterogeneity in polycythemia vera patients with JAK2 exon12 and JAK2-V617F mutations

Blood, 2008
AbstractWe studied the lineage distribution of JAK2 mutations in peripheral blood of 8 polycythemia vera (PV) patients with exon 12 mutations and in 21 PV patients with JAK2-V617F. Using a quantitative allele discrimination assay, we detected exon 12 mutations in purified granulocytes, monocytes, and platelets of 8 patients studied, but lymphoid cells ...
Li, Sai, Kralovics, Robert, De Libero, Gennaro, Theocharides, Alexandre, Gisslinger, Heinz, Skoda, Radek C.   +5 more
openaire   +4 more sources

Effects of CYT387, a Potent Novel JAK2 Inhibitor on JAK2-V617F Induced MPD

Blood, 2008
Abstract Background: The V617F mutation of JAK2 (JAK2-V617F) is present in almost all patients with polycythemia vera (PV), and approximately 50% of patients with essential thrombocythemia and idiopathic myelofibrosis. JAK2-V617F leads to constitutive activation of the JAK2 kinase, causing cytokine independent growth in cell lines and ...
Bumm, T., Tyner, J. W., Deininger, J., Loriaux, M., VanDyke, J., Druker, B. J., Burns, C. J., Fantino, E., Deininger, M. W. N.   +8 more
openaire   +2 more sources

Response:Plasma and JAK2 mutation

Blood, 2009
Response Salama et al reported on the stability of JAK2V617F DNA (17 patients) and RNA (1 patient) in whole blood specimens from subjects with V617F-positive myeloproliferative neoplasms, specifically comparing the percentage of V617F relative to wild-type sequence in granulocytes and plasma ...
Maher Albitar, Wanlong Ma, Hagop Kantarjian, Francis Giles   +3 more
openaire   +1 more source